Popular Trials
Radioisotope Therapy
177Lu-PSMA-617 + Standard Therapy for Prostate Cancer
Recruiting2 awardsPhase 3
Omaha, Nebraska
This trial tests if adding a radioactive drug to standard hormone treatments can better treat men with advanced prostate cancer. The drug targets and kills cancer cells with radiation, while standard treatments block hormones that help cancer grow.
Radioisotope Therapy
177Lu-PSMA-617 vs. ARDT for Prostate Cancer
Recruiting2 awardsPhase 3
New Orleans, Louisiana
This trial is comparing two different treatments for men with metastatic castration resistant prostate cancer who have previously been treated with an alternate androgen receptor downregulation therapy. The study will compare how well each treatment improves the participant's rPFS (progression free survival) or death.
AH-HA EHR Tool for Heart Health in Cancer Survivors
Recruiting1 award6 criteria
Cedar Rapids, Iowa
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Popular Filters
Trials for Adenocarcinoma Patients
Androgen Receptor Inhibitor
Apalutamide + Hormone Therapy for Prostate Cancer
Recruiting1 awardPhase 3
Homewood, Alabama
This trial tests whether combining apalutamide with another treatment helps men with high-risk prostate cancer undergoing radiation therapy. The treatment aims to block and reduce male hormones that fuel cancer growth, potentially preventing the cancer from spreading. Apalutamide has been developed for treating prostate cancer and has shown effectiveness.
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
Recruiting3 awardsPhase 3
Boston, Massachusetts
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Trials for Prostate Adenocarcinoma Patients
Radiation
SBRT for Prostate Cancer
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial investigates a new radiation treatment called SBRT for men with early-stage prostate cancer. SBRT uses small gold seeds and advanced imaging to precisely target and kill cancer cells while minimizing damage to healthy tissue. The goal is to provide an effective treatment with fewer side effects compared to traditional methods. SBRT is a newer radiotherapy method for prostate cancer, developed to deliver high doses of radiation with improved precision.
Procedure
TULSA Procedure vs. Radical Prostatectomy for Prostate Cancer
Recruiting1 award6 criteria
New Haven, Connecticut
This trial compares a new treatment with traditional surgery in men with prostate cancer. The goal is to see if the new treatment can effectively treat cancer while preserving important functions better than surgery. Patients will be followed for several years to assess outcomes. The new treatment is minimally invasive and uses advanced technology to target prostate tissue.
Trials for Metastatic Patients
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
Recruiting3 awardsPhase 3
Boston, Massachusetts
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Corticosteroid
Apalutamide + Abiraterone Acetate + Prednisone for Prostate Cancer
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial tests apalutamide added to a standard treatment for advanced prostate cancer. It targets patients whose cancer has spread and who haven't had chemotherapy. The treatment works by blocking and lowering male hormones that help cancer grow. Apalutamide has shown efficacy in treating different stages of prostate cancer.
Antiandrogen
Darolutamide + ADT for Prostate Cancer
Recruiting1 awardPhase 3
Abbotsford, British Columbia
This trial is testing a drug called darolutamide combined with a common hormone-lowering therapy in patients whose prostate cancer has spread but still responds to hormones. The goal is to see if this combination can effectively and safely slow down the cancer's growth. Darolutamide was approved in 2019 for a specific type of prostate cancer.
Phase 3 Trials
Androgen Receptor Inhibitor
Apalutamide + Hormone Therapy for Prostate Cancer
Recruiting1 awardPhase 3
Homewood, Alabama
This trial tests whether combining apalutamide with another treatment helps men with high-risk prostate cancer undergoing radiation therapy. The treatment aims to block and reduce male hormones that fuel cancer growth, potentially preventing the cancer from spreading. Apalutamide has been developed for treating prostate cancer and has shown effectiveness.
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
Recruiting3 awardsPhase 3
Boston, Massachusetts
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Corticosteroid
Apalutamide + Abiraterone Acetate + Prednisone for Prostate Cancer
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial tests apalutamide added to a standard treatment for advanced prostate cancer. It targets patients whose cancer has spread and who haven't had chemotherapy. The treatment works by blocking and lowering male hormones that help cancer grow. Apalutamide has shown efficacy in treating different stages of prostate cancer.
Trials With No Placebo
Antiandrogen
Enzalutamide + ADT for Metastatic Prostate Cancer
Recruiting3 awardsPhase 3
Boston, Massachusetts
This trial is testing whether a new drug, enzalutamide, is more effective than a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.